Position of the Transparency Council – Briumvi (ublituximab)
At its meeting on 17 March 2025, the Transparency Council adopted position No. 33/2025 on the evaluation of the drug Briumvi (ublituximab) under the drug program B.29 “Treatment of patients with multiple sclerosis (ICD-10: G35)”